Tiny study tracks experimental schizophrenia Drug's journey in healthy men
NCT ID NCT07455084
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will give 8 healthy men a single dose of a radioactive-labeled experimental drug called SEP-380135, which is being developed for schizophrenia. The goal is to track how the drug is absorbed, broken down, and eliminated from the body. This study does not test whether the drug works; it only gathers basic information needed for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SEP-380135 (a radioactive-labeled experimental drug)
What this could lead to
If successful, this study will help researchers understand how SEP-380135 moves through the body, which is a necessary step toward developing a potential treatment for schizophrenia.
What could go wrong
This is a very early, small study in just 8 healthy men, not people with schizophrenia. It only measures drug processing, not whether the drug works or is safe long-term. The radioactive label is safe at these levels but adds a minor risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Celerion, Inc.
Lincoln, Nebraska, 68502, United States